April 15, 2019 07:30 AM EDTUpdated May 30, 11:42 AM

This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy

John Carroll

Editor & Founder

Eight years ago, the partners at Hatteras Venture Partners reserved 20% of their fund for seed-stage plays. The impact of sequencing was spreading, driving a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

This ven­ture play­er is plot­ting $200M in new biotech in­vest­ing — and they’re dou­bling down on a start­up-rich strat­e­gy

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers